MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Vevorisertib trihydrochloride

CAS No. : 1416775-08-0

MCE 站：Vevorisertib trihydrochloride

产品活性：Vevorisertib (ARQ 751) trihydrochloride 是选择性、变构、pan-AKT 和 AKT1-E17K 突变抑制剂，可有效抑制 AKT 的磷酸化。Vevorisertib trihydrochloride 对 AKT1 和 AKT1-E17K 的 Kd 值分别为 1.2 nM 和 8.6 nM。Vevorisertib trihydrochloride 对 AKT1、AKT2 和 AKT3 的 IC₅₀ 值分别为 0.55、0.81 和 1.3 nM。 Vevorisertib trihydrochloride 可用于癌症的研究。

研究领域：PI3K/Akt/mTOR

作用靶点：Akt

In Vitro: Vevorisertib trihydrochloride (0, 12, 33, 111, 333, 1000 nM, 2 hours) inhibits phosphorylation of AKT1-E17K.
Vevorisertib trihydrochloride (1 μM for 2 hours; NIH 3T3 cells are transfected with either pcDNAAKT-WT-GFP or pcDNA-E17K-GFP) inhibits plasma membrane translocation of AKT-WT and AKT1-E17K irrespective of the presence of growth factors.
Vevorisertib trihydrochloride (5 μM) exhibites 57% inhibition of full-length AKT1.
Vevorisertib trihydrochloride (0, 0.012, 0.037, 0.11, 0.33, 1 μM; 2 hours) shows a dose-dependent effect on mTORC1 and AKT direct substrates including PRAS40, GSK3β, FOXO, BAD, and AS160 in cancer cell lines.
Vevorisertib trihydrochloride has anti-proliferative effect on esophageal, breast, and head and neck cancer cells (GI₅₀ < 1 μM).
Vevorisertib trihydrochloride exhibits strong anti-proliferative activity in PIK3CA mutant cell lines.
Vevorisertib trihydrochloride (MK-4440)/imatinib mesylate (IM) combination shows cell cycle arrest, and increases cell death of gastrointestinal stromal tumor (GIST) cells.
Vevorisertib trihydrochloride exhibits strong anti-proliferative activity in PIK3CA mutant cell lines:

In Vivo: Vevorisertib trihydrochloride (25, 50 and 75 mg/kg; p.o.; 5 days dosing followed by a 4 day dosing holiday for 20 days) shows potent tumor growth inhibition of 68, 78 and 98%, respectively.
Vevorisertib trihydrochloride (5, 10, 20, 40, 80, and 120 mg/kg; p.o. daily for ten days) shows tumor growth inhibition of 29, 33, 50, 73, 83, and 92%, respectively.
Vevorisertib trihydrochloride reachs C_max plasma concentrations of ≥2 μM.
Vevorisertib trihydrochloride is generally well-tolerated at dose levels up to 120 mg/kg.
Vevorisertib trihydrochloride (MK-4440)/IM combination shows superior efficacy in an IM-sensitive preclinical model of GIST compared with either single agent.

相关产品：MK-2206 dihydrochloride  |  SC79  |  Ipatasertib  |  Capivasertib  |  Honokiol  |  GSK-690693  |  AKT inhibitor VIII  |  Artemisinin  |  Recilisib  |  Guggulsterone  |  Miransertib  |  Oridonin  |  Perifosine  |  Afuresertib  |  Scutellarin  |  Triciribine  |  A-443654  |  SU6656  |  α-Linolenic acid  |  Uprosertib  |  Isobavachalcone  |  YS-49  |  Deguelin  |  Urolithin B  |  Miltefosine  |  CCT128930  |  A-674563 hydrochloride  |  LM22B-10  |  AT13148

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  染料试剂  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。